Oppenheimer initiated coverage on MoonLake Immunotherapeutics with a new price target
$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $104.00